Characterise the natural history of IPF vs non-IPF ILD in terms of FVC lung function decline

To utilize historical patient records to identify “non strictly IPF” patients with progressive lung fibrosis who may benefit from pharmacological management with approved IPF therapies by characterizing and comparing (i) clinical presentation (over time); (ii) characteristics (clinical and demographic) at time of diagnosis and (iii) clinical progression of patients diagnosed with IPF and those with “non strictly IPF” progressive fibrotic lung conditions.

Lead Investigators:
Luca Richeldi
Mark Jones
David Price

Research Team:
Alison Chisholm, UK
Anjan Nibber, UK
Status: Proposed Study, Seeking Funding

Documents and Publications:
Final Publications
Additional Material

Leave a Reply

Your email address will not be published. Required fields are marked *